Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Market Cap	188.36M +212.9%
Revenue (ttm)	n/a
Net Income	-78.54M
EPS	-5.90
Shares Out	17.74M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	318,775
Open	10.57
Previous Close	10.59
Day's Range	10.44 - 10.97
52-Week Range	5.90 - 20.56
Beta	2.79
Analysts	Strong Buy
Price Target	45.60 (+329.38%)
Earnings Date	May 5, 2026

About CRBP

Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 36
• Stock Exchange: NASDAQ
• Ticker Symbol: CRBP
• Website: https://www.corbuspharma.com

Analyst Summary

According to 5 analysts, the average rating for CRBP stock is "Strong Buy." The 12-month stock price target is $45.6, which is an increase of 329.38% from the latest price.

Price Target

$45.6

(329.38% upside)

Analyst Consensus: Strong Buy